Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;11(3):647-652.
doi: 10.1016/j.tranon.2018.02.021. Epub 2018 Mar 30.

Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma

Affiliations

Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma

Cristina Mansilla et al. Transl Oncol. 2018 Jun.

Abstract

Multiple myeloma (MM) is a very heterogeneous disease, characterized by multiple cytogenetic aberrations on plasma cells (PC) that have been traditionally used to predict the outcome of the disease. A mayor issue on the analysis of PC is the sometimes low infiltration of these cells in the bone marrow that hampers cytogenetic studies. To solve this problem we have optimized a selection strategy based on PC immunomagnetic isolation that has allowed us to lower to 1% the minimal PC infiltration requirement without loss of purity, enabling to perform genetic analysis. In this study, we have analyzed 153 bone marrow samples of patients suspected of MM, collected from February 2015 to May 2017 by the Genetics service of the Complejo Hospitalario de Navarra. Clinical characteristics of the patients and PC immunophenotyping, conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) analyses have been assessed on these samples. In our cohort 90% of the samples had cytogenetic abnormalities, among them 50% presented immunoglobulin rearrangements, 41.9% showed 1q gains, 29.7% showed 1p deletions and 33% presented TP53 deletion.

PubMed Disclaimer

Similar articles

References

    1. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., Fonseca R., Rajkumar S.V., Offord J.R., Larson D.R. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. - PubMed
    1. De Gramont A., Grosbois B., Michaux J.L., Peny A.M., Pollet J.P., Smadja N., Krulik M., Debray J., Bernard J.F., Monconduit M. IgM myeloma: 6 cases and a review of the literature. Rev Med Interne. 1990;11(1):13–18. - PubMed
    1. Dierlamm T, Laack E, Dierlamm J, Fiedler W, Hossfeld DK. IgM myeloma: a report of four cases. Ann Hematol. 2002;81(3):136–139. - PubMed
    1. Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park) 2013;27(8):798–803. - PubMed
    1. Tchinda J., Volpert S., Kropff M., Berdel W.E., Kienast J., Meinhardt F., Horst J. Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization. Am J Clin Pathol. 2004;122(6):875–882. - PubMed